A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

scientific article published on 13 February 2016

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1028230999
P356DOI10.1007/S10549-016-3701-7
P698PubMed publication ID26875185

P50authorHope RugoQ55975497
Amy Jo ChienQ87289244
Pamela MunsterQ90470925
Laura EssermanQ91960202
Laura J Van't VeerQ92380286
Mark M MoasserQ92502776
Michelle E MeliskoQ92576217
Christina YauQ114338711
P2093author name stringAndrew H Ko
Denise M Wolf
Emmett Schmidt
W Michael Korn
Craig Fancourt
R Katie Kelley
Alyson Cockerill
P2860cites workEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Q24633878
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerQ24641848
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.Q27824766
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Q27824819
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerQ27824847
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerQ27851414
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signalingQ27851446
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.Q27851582
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsQ27851678
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneQ27860693
Exploiting the PI3K/AKT pathway for cancer drug discoveryQ29615120
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerQ29616112
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersQ34679149
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.Q35103514
Perturbations of the AKT signaling pathway in human cancerQ36313181
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancerQ36476312
Biomarkers of response to Akt inhibitor MK-2206 in breast cancerQ37168778
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerQ37380424
Modeling precision treatment of breast cancerQ37608340
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsQ37690991
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.Q38944616
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cellsQ39223582
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancerQ41756399
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasisQ44259982
Dose-finding in phase I clinical trials based on toxicity probability intervals.Q51907391
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectpaclitaxelQ423762
trastuzumabQ412616
MK-2206Q25100065
P304page(s)521-530
P577publication date2016-02-13
P1433published inBreast Cancer Research and TreatmentQ326085
P1476titleA phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
P478volume155

Reverse relations

cites work (P2860)
Q64226327Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal
Q52581752Current therapeutic landscape for advanced gastroesophageal cancers.
Q92280905Genome atlas analysis based profiling of Akt pathway genes in the early and advanced human prostate cancer
Q89592800MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
Q28072254Maximising the potential of AKT inhibitors as anti-cancer treatments
Q100752660Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
Q88598954Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial
Q55353691Recent Advances in the Treatment of Breast Cancer.
Q98289829Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo
Q39312902The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Q37743486mTOR function and therapeutic targeting in breast cancer

Search more.